{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:17:56Z","timestamp":1760145476791,"version":"build-2065373602"},"reference-count":15,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Rationale: Evaluating the long-term safety and efficacy of peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumors (mNETs) who have undergone prior bland hepatic transarterial embolization (TAE). Methods: Retrospective review of mNET patients who received PRRT with 177Lu-DOTATATE between 4\/2018 and 02\/2022 with and without prior TAE. The most recent clinical, imaging, and laboratory findings, including hepatic Common Terminology Criteria for Adverse Events v5.0, were compared to pre-PRRT. Results: 171 patients (95 M, 76 F, median age = 66) with mNET of different primary sites (9 foregut, 100 midgut, 9 hindgut, 44 pancreas, 9 unknown) received at least 1 cycle of PRRT with at least 6 months of follow-up, 110 of whom were embolization-na\u00efve and 61 who had prior TAE. The median follow up was 22 months (range: 6\u201343). Patients with prior TAE had higher liver tumor burden on average than patients without prior TAE; however, the difference was not statistically significant (p = 0.06). There was no significant difference in the rates of G3 or G4 hepatotoxicity (p = 0.548 and p = 0.999, respectively) in patients who underwent prior TAE and those who were TAE-na\u00efve. The hepatic progression-free survival was 22.9 months in TAE-na\u00efve patients and 25.7, 20.2, and 12.8 months in patients with 1, 2, and 3 prior TAE treatments, respectively. Conclusion: Peptide receptor radionuclide therapy following transarterial bland embolization for mNET is safe and effective.<\/jats:p>","DOI":"10.3390\/cancers16152703","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T08:51:42Z","timestamp":1722329502000},"page":"2703","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors"],"prefix":"10.3390","volume":"16","author":[{"given":"Adam","family":"Alayli","sequence":"first","affiliation":[{"name":"University of South Florida Morsani College of Medicine, Tampa, FL 33602, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang","family":"Ngo","sequence":"additional","affiliation":[{"name":"University of South Florida Morsani College of Medicine, Tampa, FL 33602, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6297-3022","authenticated-orcid":false,"given":"Dhiraj","family":"Sikaria","sequence":"additional","affiliation":[{"name":"University of South Florida Morsani College of Medicine, Tampa, FL 33602, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Altan","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Salloum","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8405-218X","authenticated-orcid":false,"given":"Jonathan R.","family":"Strosberg","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-2414","authenticated-orcid":false,"given":"Taymeyah E.","family":"Al-Toubah","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Kis","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mintallah","family":"Haider","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghassan","family":"El-Haddad","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2012.44.5924","article-title":"Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors","volume":"31","author":"Strosberg","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000457957","article-title":"ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors","volume":"105","author":"Pavel","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hpb.12326","article-title":"Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): Guidelines from the NET-Liver-Metastases Consensus Conference","volume":"17","author":"Kennedy","year":"2015","journal-title":"HPB (Oxford)"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","first-page":"7","article-title":"A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: Updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.7150\/thno.77219","article-title":"Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors","volume":"12","author":"Jiang","year":"2022","journal-title":"Theranostics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/RLU.0000000000001818","article-title":"Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors","volume":"42","author":"Hamiditabar","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(20)30027-9","article-title":"Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): A single-centre, single-arm, open-label, phase 2 study","volume":"21","author":"Braat","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00270-019-02350-2","article-title":"Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy","volume":"43","author":"Braat","year":"2020","journal-title":"Cardiovasc. Intervent. Radiol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/15\/2703\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:26:10Z","timestamp":1760109970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/15\/2703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":15,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["cancers16152703"],"URL":"https:\/\/doi.org\/10.3390\/cancers16152703","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}